Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Review Of Neurotherapeutics 2009, 9: 319-321. PMID: 19271940, DOI: 10.1586/14737175.9.3.319.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodiesDrug EvaluationHumansInterleukin-12Interleukin-23Multiple SclerosisTreatment FailureConceptsMultiple sclerosisRelapsing-remitting multiple sclerosisIL-12/ILPhase II clinical trialDose-ranging studyPhase I trialMechanism of actionRadiologic improvementAdvanced diseaseTherapy failsIL-23I trialIL-12/23IL-12Study inclusionPlacebo controlClinical trialsSubcutaneous injectionTreatment groupsAnimal modelsSclerosisPatientsAntibodiesTreatment effectsPhase II